After finishing at $17.75 in the prior trading day, Silk Road Medical Inc (NASDAQ: SILK) closed at $16.88, down -4.90%. In other words, the price has decreased by -$0.87 from its previous closing price. On the day, 1132730 shares were traded.
Ratios:
Our goal is to gain a better understanding of SILK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.97 and its Current Ratio is at 7.95. In the meantime, Its Debt-to-Equity ratio is 0.56 whereas as Long-Term Debt/Eq ratio is at 0.55.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stifel on January 19, 2024, Upgraded its rating to Buy and sets its target price to $20 from $9 previously.
On January 03, 2024, Lake Street started tracking the stock assigning a Buy rating and target price of $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 05 when Buchanan Lucas W. sold 9,877 shares for $17.17 per share. The transaction valued at 169,578 led to the insider holds 500,925 shares of the business.
Davis Andrew S. sold 5,481 shares of SILK for $94,103 on Mar 05. The Chief Commercial Officer now owns 287,773 shares after completing the transaction at $17.17 per share. On Mar 05, another insider, Ruedy Richard, who serves as the EVPClin&Reg.Affairs&QA of the company, sold 3,800 shares for $17.17 each. As a result, the insider received 65,242 and left with 205,711 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SILK now has a Market Capitalization of 661.27M and an Enterprise Value of 557.12M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.73 while its Price-to-Book (P/B) ratio in mrq is 4.37. Its current Enterprise Value per Revenue stands at 3.15 whereas that against EBITDA is -12.36.
Stock Price History:
Over the past 52 weeks, SILK has reached a high of $48.44, while it has fallen to a 52-week low of $6.08. The 50-Day Moving Average of the stock is 14.80, while the 200-Day Moving Average is calculated to be 17.73.
Shares Statistics:
The stock has traded on average 888.09K shares per day over the past 3-months and 1.05M shares per day over the last 10 days, according to various share statistics. A total of 39.17M shares are outstanding, with a floating share count of 36.88M. Insiders hold about 5.85% of the company’s shares, while institutions hold 104.41% stake in the company. Shares short for SILK as of Feb 15, 2024 were 3.6M with a Short Ratio of 4.05, compared to 3.43M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.24% and a Short% of Float of 9.42%.
Earnings Estimates
Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of -$0.4 for the current quarter, with a high estimate of -$0.36 and a low estimate of -$0.42, while EPS last year was -$0.43. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.32 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.32 and -$1.5 for the fiscal current year, implying an average EPS of -$1.39. EPS for the following year is -$1.3, with 9 analysts recommending between -$1.17 and -$1.57.
Revenue Estimates
9 analysts predict $44.68M in revenue for the current quarter. It ranges from a high estimate of $45M to a low estimate of $43.8M. As of the current estimate, Silk Road Medical Inc’s year-ago sales were $40.69M, an estimated increase of 9.80% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $49.07M, an increase of 8.30% less than the figure of $9.80% in the same quarter last year. There is a high estimate of $50.1M for the next quarter, whereas the lowest estimate is $47.6M.
A total of 9 analysts have provided revenue estimates for SILK’s current fiscal year. The highest revenue estimate was $196.7M, while the lowest revenue estimate was $194M, resulting in an average revenue estimate of $195.92M. In the same quarter a year ago, actual revenue was $177.13M, up 10.60% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $217.79M in the next fiscal year. The high estimate is $225.41M and the low estimate is $213M. The average revenue growth estimate for next year is up 11.20% from the average revenue estimate for this year.
